Vosoritide Injection [Voxzogo]
Preclinical
BioMarin PharmaceuticalVosoritide Injection [Voxzogo] is one of 9 therapeutic programs targeting Achondroplasia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in Achondroplasia
#DrugCompanyPhaseTrials
1Voxzogo
BioMarin PharmaceuticalPhase 2
BMN 333
BioMarin PharmaceuticalPhase 3
Truseltiq
HHelsinn Healthcare SA
Phase 2
Yuviwel
Ascendis PharmaPhase 2
ABSK061
AAbbisko Therapeutics Co, Ltd
Phase 2
TYRA-300
TTyra Biosciences, Inc
Phase 2
Genotropin
EMD SeronoPreclinical
Transcon CNP
AAscendis Pharma Growth Disorders A/S
Phase 2
Vosoritide Injection [Voxzogo]
BioMarin PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company